IGA Nephropathy Foundation
Building Leadership
IgA nephropathy, also known as Berger's Disease, is an autoimmune disease that occurs when clumps of antibodies are deposited in the kidneys, causing inflammation and kidney damage. Clumps of immunoglobulin A (IgA) and other antibodies damage the glomeruli, tiny blood vessels in the kidneys that filter blood, causing the kidneys to leak blood and protein into the urine. The damage may also lead to the scarring of the nephrons, the filtering units where the glomeruli are located.
Last updated 04/30/2025
Clinical
Disease Class
Renal diseases
Body Systems
Renal / Urinary / Excretory
Organs
Kidneys
Known Genetic Link
No, the disease is not known to have a genetic basis
causative_genes
None specified / unknown
contributory_genes
None specified / unknown
Type of Inheritance
Not specified / unknown
Newborn Screening
No
Disease Mechanism(s)
Autoimmune
Age of Onset
Adolescence (12-17)
Adulthood (age 18-64)
Early childhood (age 1+-5)
Elderly (age 65+)
Middle childhood (6-11)
Average Age at Diagnosis
Adolescence (12-17)
Adulthood (age 18-64)
Life Expectancy
Adulthood (age 18-64)
Elderly (age 65+)
Affected Sex(es)
Female
Male
National Prevalence
10000+
Global Prevalence
10000+
National Incidence
Unknown
Global Incidence
Unknown
Populations and/or ancestry with higher prevalence
IgA Nephropathy is known to affect Asian and South Asians disproportionately. 30% of our patient population is of this ethnicity.
Symptoms / Phenotypes
anxiety
fatigue
flank pain
headaches / migraines
hematuria
proteinuria
Biomarkers
Diagnostic
· UAB set first biomarkers for IgA Nephropathy
Existing Therapies
FDA-Approved for Symptom Relief
· Ace & Arbs Steroids
FDA-Approved to Cure or Modify the Disease
· Sparsentan, Filspari currently on the market
Organizational & Research
Cell Lines
None
Cell Lines, Institution
None
Cell Lines, share
N/A
Disease Model
None
Disease Model, share
N/A
Clinical Trial Role
Data analysis
Data sharing
Focus group
Meeting with regulators
Outcome measures, development
Recruitment and outreach, patients
Recruitment and outreach, trial sites/physicians
Results dissemination, publication
Study material design, review (not protocol)
Study protocol design, review
Travel coordination
Biobank, Institution
None
Center of Excellence, Institution
Not specified
Center of Excellence, Involvement
Consulted
Registry
Yes, we have a registry that we created
Data Collected, Registry
Clinical data
Electronic health records/electronic medical records
Genetic data
Longitudinal natural history data
Medication usage
Patient-reported data
Data Entered by, Registry
Patients
Platform, Registry
Matrix
Natural History Study
Yes, we have collaborated on a natural history study
Data Collected, Natural History Study
Medication usage
Patient-reported outcomes
Platform, Natural History Study
Matrix
FDA Patient Listening Session
Yes
FDA Patient-Focused Drug Development (PFDD) Program
Yes
ICD Codes
Yes, we have an ICD-10 code specific to our exact disease
Diagnostic Guidelines
Yes, we have guidance available on our website
Science Advisory Board Policies
Yes, willing to share SAB policies
Research Network Policies
Has CRN but no policies
Research Roadmap
Yes we have a Research Roadmap, and will share policies
International Chapters
North America
International Partners
None